-
ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Pluripotent Stem Cell Line ESI-053.
-
IMS001 is an investigational, allogeneic, MSC product derived from a human embryonic stem cell line.
-
It is assumed to be the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA for patients with MS.
denovoMATRIX releases isoMATRIX: Cell and Gene Therapy’s first high-yield MSC isolation technology
DRESDEN, Germany, December 15, 2021 / BioInformant / — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a new technology for bringing down costs and increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The technology termed isoMATRIX, is designed to isolate MSCs in xeno-/serum-free conditions with high efficiency and stemness enabling rapid cell expansion for radically reduced cost of goods (COGs) for cell therapy manufacturers.
Cord Blood Banking – Present and Future Outlook
Cord blood banking is defined as the collection and storage of stem cells present within the umbilical cord blood of a newborn for future medical use. Umbilical cord blood is rich in a type of stem cell known as a hematopoietic stem cell (HSC). A large market for the storage of these cells has come into existence over the past 30 years, with public and private cord blood banks now present in all major healthcare markets worldwide. [Read more…]
CAR-T Cell Therapeutics: A Multi-Billion Dollar Market
CAR-T is a promising type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the capacity to recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, proliferating clinical trials, aggressive M&A activity, and lucrative IPOs have created a robust CAR-T cell market. [Read more…]
Winner of the European EIC Accelerator program, EVerZom accelerates the industrialization of its exosome bioproduction platform for regenerative medicine
Paris, 18 November 2021 — EVerZom, a biopharmaceutical company specialized in the biomanufacturing of extracellular vesicles (or exosomes), announced today that it has obtained non-dilutive funding of €2.5 million as the winner of the European EIC Accelerator competition (Horizon Europe). This funding will enable the company to transfer its extracellular vesicle biomanufacturing technology for a first clinical grade batch production and to accelerate the scale-up of its production capabilities by developing a process compatible with clinical Phase 2/3 for the pharmaceutical industry. [Read more…]
- « Previous Page
- 1
- …
- 154
- 155
- 156
- 157
- 158
- …
- 336
- Next Page »